JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD B. Pharmacy IV PHARMACEUTICAL REGULATORY SCIENCE Previous Question Paper (February-2022 - R17)

Lead discovery is the initial phase of drug discovery aimed at identifying a chemical compound, known as a lead, that exhibits a desired biological activity against a specific therapeutic target. This lead serves as the starting point for chemical optimization to improve potency, selectivity, and pharmacokinetic properties.

Key approaches for lead discovery include:

• High-Throughput Screening (HTS): Involves testing large libraries of synthetic or natural compounds against a biological target using automated systems to identify hits.
• Structure-Based Drug Design (SBDD): Utilizes knowledge of the 3D structure of the target protein (obtained via X-ray crystallography or NMR) to design molecules that fit precisely into the active site.
• Fragment-Based Lead Discovery (FBLD): Focuses on identifying small molecular fragments that bind weakly to the target and then growing or linking these fragments to create higher-affinity leads.
• Natural Product Screening: Investigates compounds derived from plants, marine organisms, or microorganisms, which often possess complex structural scaffolds and inherent biological activity.
• Virtual Screening: Uses computational methods and molecular docking simulations to predict the binding affinity of large virtual chemical libraries before physical synthesis and testing.

Pharmacological and safety pharmacological studies are critical in drug discovery to bridge the gap between initial hit identification and clinical trials, ensuring the candidate is both effective and safe for human use.

Pharmacological studies (Pharmacodynamics) determine the mechanism of action, dose-response relationships, and the therapeutic potential of the lead compound. These studies confirm that the drug interacts with the intended target to produce the desired physiological effect, providing the proof-of-concept necessary to justify further development.

Safety pharmacological studies are specifically designed to assess the effects of a drug on vital organ systems (cardiovascular, respiratory, and central nervous system) at therapeutic and supra-therapeutic doses. The importance of these studies includes:

• Risk Mitigation: Identifying potential adverse effects early in the pipeline prevents the costly failure of drugs during clinical trials.
• Regulatory Compliance: International guidelines (such as ICH S7A) mandate these studies to ensure that the drug does not pose life-threatening risks, such as QT interval prolongation or respiratory depression.
• Therapeutic Index Determination: By establishing the margin between effective doses and toxic doses, these studies define the safety profile, which is essential for determining the initial safe starting dose for human clinical trials.